- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Seagen, after $42M victory, suffers loss in ADC patent feud with Daiichi | ||
| Fr | Two deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again | ||
| Fr | Pfizer in catch-up mode with Merck shows data that could fetch Prevnar 20 a key approval | ||
| Fr | AstraZeneca's Enhertu breaks more ground, nabbing fast FDA nod in HER2-mutant lung cancer | ||
| Fr | Fierce Pharma Asia-Enhertu's historic nod; Hutchmed's trial wins; BeiGene, Novartis' liver cancer readout | ||
| Do | GSK's rotavirus vaccine temporarily runs short, and 'manufacturing challenges' are to blame | ||
| Do | EMA warns of shortage of IVF drug Cetrotide because of Merck KGaA manufacturing issue | ||
| Do | After Roe ruling, Bayer enlists lobbyists to fight for contraceptive access | ||
| Do | As orders slow to a halt, J&J partner Aspen may have to redirect manufacturing efforts: report | ||
| Do | Blueprint exec spots key Ayvakit readout, dealmaking plan as 'independent precision therapy company' | ||
| Do | Market reaction to Sanofi's upcoming litigation over Zantac is 'overblown,' analysts say | ||
| Do | Moderna CEO touts plan for triple combo respiratory shot in 'three to five years': report | ||
| Mi | Novartis' new rare disease drug Vijoice named as an 'empty vessel poised to be filled' | ||
| Mi | Bristol Myers, in close CAR-T race with J&J and Legend, touts Abecma win in earlier myeloma | ||
| Mi | GSK, IQVIA team up on 'Vaccine Track' to spotlight shot trends across the US | ||
| Mi | New CEO Maselli extends Catalent's expansion blitz with $475M buyout of CDMO Metrics | ||
| Mi | Something to frown about: Revance slapped with another FDA citation, putting approval hopes for Botox rival in limbo | ||
| Mi | FDA relaxes impurity limit on Merck's blockbuster diabetes med Januvia after testing flags possible carcinogen. Are recalls next? | ||
| Mi | Bavarian Nordic's monkeypox vaccine supply quintupled in US thanks to FDA 'dose-sparing' switch | ||
| Di | No DIY mole removal. FDA cracks down on Amazon, other companies for selling unapproved products | ||
| Di | In warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare disease drug | ||
| Di | Novartis, BeiGene's PD-1 hits goal in first-line liver cancer. Should Roche worry about Tecentriq? | ||
| Di | After FDA snub, Hutchmed touts promising data for two other oncology meds | ||
| Di | Amid $1B downsizing, Biogen lists Boston-area office space for sublease | ||
| Di | BARDA backs Opiant to help get nasal opioid overdose drug over the FDA line |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
